Inmune Bio, Inc.

Listed Company

INMBCIK 0001711754NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)NevadaFY ends Dec 31

Period

FY 2025

Revenue

$50.0K

Net Income

$-45.90M

Total Assets

$32.35M

Equity

$23.52M

Shares Out

26.59M

Op. Cash Flow

$-22.60M

Business

Inmune Bio, Inc. develops immunotherapies that target innate immune dysfunction to treat cancer, neurodegenerative and inflammatory diseases. Its main products include INKmune (an NK‑cell priming therapy), XPro1595 (a dominant‑negative TNF biologic for neuroinflammation), CORDStrom (a pooled human umbilical cord mesenchymal stromal cell platform) and related candidates such as INB03. Business is organized around three therapeutic platforms—DN‑TNF biologics, NK‑cell priming (INKmune) and MSC‑based CORDStrom—alongside R&D, manufacturing and licensing. Clinical development and trials occur across North America, Europe, Australia and other international markets through clinical sites, collaborations and potential commercial partners.

Summary from filing dated 2025-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
REVENUE	50,000	14,000	155,000	374,000	181,000
General and administrative	10	9	10	9	9
Research and development	21	33	20	17	21
Impairment of acquired in-process research and development intangible assets	17	—	—	—	—
Total operating expenses	47	43	30	26	29
LOSS FROM OPERATIONS	−47	−43	−30	−26	−29
OTHER INCOME, NET	1	553,000	−267,000	—	−1
NET LOSS	−46	−42	−30	−27	−30
Net loss per common share basic (in Dollars per share)	−1.86	−2.11	−1.67	−1.52	−1.88
Net loss per common share diluted (in Dollars per share)	−1.86	−2.11	−1.67	−1.52	−1.88
Weighted average number of common shares outstanding basic (in Shares)	25	20	18	18	16
Weighted average number of common shares outstanding diluted (in Shares)	25	20	18	18	16
Gain (loss) on foreign currency translation	−162,000	224,000	−100,000	−700,000	−10,000
Total comprehensive loss	−46	−42	−30	−28	−30

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	25	21	36	52	75
Research and development tax credit receivable	4	1	2	—	—
Other tax receivable	257,000	228,000	537,000	362,000	—
Prepaid expenses and other current assets	595,000	331,000	2	4	14,000
TOTAL CURRENT ASSETS	30	23	40	65	83
Equipment, net	955,000	—	—	—	—
Operating lease right of use asset	914,000	307,000	414,000	507,000	726,000
Other assets	595,000	79,000	131,000	99,000	99,000
Acquired in-process research and development intangible assets	—	17	17	17	17
TOTAL ASSETS	32	40	57	82	100
Accounts payable and accrued liabilities	8	7	8	5	4
Deferred liabilities	—	517,000	489,000	616,000	474,000
Operating lease, current liability	623,000	140,000	119,000	87,000	72,000
TOTAL CURRENT LIABILITIES	8	7	18	11	4
Long-term operating lease liability	411,000	244,000	397,000	526,000	704,000
TOTAL LIABILITIES	9	7	19	22	20
COMMITMENTS AND CONTINGENCIES	—	—	—	—	—
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding	—	—	—	—	—
Common stock, $0.001 par value, 200,000,000 shares authorized, 26,585,258 and 22,280,451 shares issued and outstanding, respectively	27,000	22,000	18,000	18,000	18,000
Additional paid-in capital	233	196	159	152	144
Accumulated other comprehensive loss	−737,000	−575,000	−799,000	−699,000	1,000
Accumulated deficit	−209	−163	−121	−91	−64
TOTAL STOCKHOLDERS EQUITY	24	32	37	60	80
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	32	40	57	82	100

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation	10	8	7	7	5
Accretion of debt discount	0	79,000	—	—	—
Gain on settlement of accounts payable	−626,000	—	—	—	—
Depreciation expense	84,000	—	—	—	—
Research and development tax credit receivable	−3	724,000	6	—	—
Other tax receivable	−29,000	309,000	−175,000	229,000	−478,000
Prepaid expenses and other current assets	−264,000	1	—	−2	−2
Prepaid expenses related party	0	142,000	−108,000	—	—
Other assets	−516,000	52,000	−32,000	—	−99,000
Accounts payable and accrued liabilities	2	−1	3	1	2
Accounts payable and accrued liabilities related parties	—	−10,000	26,000	−71,000	46,000
Deferred liabilities	−517,000	28,000	−127,000	142,000	—
Operating lease liability	43,000	−25,000	−4,000	−33,000	46,000
Net cash used in operating activities	−23	−33	−12	−23	−29
Purchase of fixed assets	−1	—	—	—	—
Net cash used in investing activities	−1	—	—	—	−15
Net proceeds from sale of common stock and warrants	28	28	775,000	699,000	80
Cash proceeds for amendment of warrants	67,000	—	—	—	—
Exercise of warrants for cash	1,000	—	—	30,000	18,000
Repayment of debt	—	−10	−5	—	—
Net proceeds from the exercise of stock options	—	422,000	—	—	1
Net cash provided by financing activities	28	18	−4	729,000	96
Impact on cash from foreign currency translation	−159,000	224,000	−100,000	−700,000	−10,000
NET INCREASE (DECREASE) IN CASH	4	−15	−16	−23	53
Cash paid for income taxes	—	—	—	—	—
Cash paid for interest expense	—	2	2	1	559,000
Right of use assets obtained in exchange for lease obligations	702,000	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro